Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05832229 · ClinicalTrials.gov registry record · Phase 2
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
A Phase 2 study of Cirrhosis and Cirrhosis, Liver, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
- 13
- Study locations
NCT05832229: Recruiting Phase 2 study of Cirrhosis and Cirrhosis, Liver, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT05832229 is a Phase 2 study of Cirrhosis and Cirrhosis, Liver that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 256 participants, below the 90,404-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05832229, a Phase 2 study of Cirrhosis and Cirrhosis, Liver, is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Primary Outcome
Mean change in liver stiffness as measured in kilopascal with Vibration-Controlled Transient Elastography between study entry and week 96. Range: 2 to 75 kilopascal. Higher stiffness indicates increased disease progression
Conditions Studied
Interventions
- DRUG Rosuvastatin
Study Locations (13)
California
- University of California San Diego NAFLD Research Center - La Jolla
- Keck Medical Center of USC - Los Angeles
- LAC + USC Medical Center - Los Angeles
- UCSF/Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
- UCSF Medical Center - San Francisco
New York
- New York Presbyterian/Weill Cornell - New York
- Columbia University Iriving School of Medicine - New York
Florida
- University of Miami Health System - Miami
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Duke Liver Center - Durham
Ohio
- Cleveland Clinic - Cleveland
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2023-12-07 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 2 |
What NCT05832229 shows while recruiting
NCT05832229 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 90,404-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 8 conditions, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which Rosuvastatin is the first listed.
NCT05832229 lists 13 locations in 8 states (California, New York, Florida).
Frequently Asked Questions
What is clinical trial NCT05832229 about?
NCT05832229 is a clinical study titled "Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States". This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
What is the current status of trial NCT05832229?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2023-12-07. Estimated completion is 2029-08-31.
What conditions does trial NCT05832229 study?
This clinical trial studies the following conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced.
What interventions are being tested in trial NCT05832229?
The interventions under investigation include: Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT05832229?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05832229 being conducted?
This trial has 13 study locations across California, Florida, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05832229's enrollment target sits among peer trials
256 11th of 53 higher than 43 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
RECRUITING · Phase 2
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
-
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI